FH535 is primarily used in biochemical and pharmacological research as an inhibitor of the Wnt/β-catenin signaling pathway. This pathway plays a critical role in cell proliferation, differentiation, and stem cell regulation, and its dysregulation is associated with various cancers. FH535 helps in studying the mechanism of Wnt signaling by reducing β-catenin-mediated transcription, making it a valuable tool in cancer research, particularly in models of colorectal and liver cancer. It is also employed in metabolic disease research, where it modulates PPAR (peroxisome proliferator-activated receptor) activity, affecting glucose metabolism and adipogenesis. Due to its dual action on Wnt and PPAR pathways, FH535 supports investigations into the crosstalk between oncogenic signaling and metabolic regulation. Its application is mainly limited to in vitro and preclinical studies, aiding in target validation and pathway analysis.